佳人破瓜含羞叫床|久久婷五月天|国产熟女人妻一区二区三区四区 |久久久精品人妻一区二区

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73197KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3
名稱 KIF5B(E15)-RET(E12) V804E/BaF3
型號(hào) CBP73197
報(bào)價(jià)
特點(diǎn) KIF5B(E15)-RET(E12) [V804E]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73197
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804E]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


2. Sanger of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


3. Anti-proliferation assay

KIF5B(E15)-RET(E12) V804E/BaF3


Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804E Cells (C1).





如果你對(duì)CBP73197KIF5B(E15)-RET(E12) V804E/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站

佳人破瓜含羞叫床|久久婷五月天|国产熟女人妻一区二区三区四区 |久久久精品人妻一区二区

久久夜色噜噜噜av一区二区| 久久国产乱子伦精品| 亚洲欧美在线精品| 日韩欧美成人网| 精品人妻午夜| 欧美人妻精品久久久一区二区| 成人免费毛片色戒| 97人妻人人澡人人| 久久一区二区电影| 久久亚洲国产精品| 秋霞电影网午夜| 国内精品国产成人国产三级| 亚洲综合久久久久| 69精产国品一二三产品价格| jizz欧美大全| 女的被弄到高潮娇喘喷水视频| 久久九九爱| 国产精品精东影业| 国产女人高潮的av毛片| 99久久精品国产免费看不卡| av在线黄色| good电影三级理论韩国| 人人妻人人澡人人爽人人爽欧美 | 中文字幕免费一区| 成人av在线直播| 色多多一区二区| 蜜桃成熟时之三人同眠| 国产精品av久久久久久麻豆网| 国产成人短视频在线观看| 欧美日韩成人精品| 欧美内射网| 欧洲美熟女乱又伦av影片| 国产亚洲精品久久久久久久久无几年桃| 国产a久久精品一区二区三区 | 18sexfreevideo| 日韩精品无码一区二区三区不卡| 又色又爽又高潮免费观看| 日韩一区av| www.成人在线视频| 国产肉体xxxxx裸体i37| 91麻豆精品国产91久久久资源速度|